Lipocine (NASDAQ:LPCN) Now Covered by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Lipocine (NASDAQ:LPCN) in a research note released on Saturday. The brokerage issued a hold rating on the specialty pharmaceutical company’s stock.

Lipocine Stock Performance

NASDAQ:LPCN opened at $3.63 on Friday. The firm’s fifty day moving average is $3.25 and its two-hundred day moving average is $4.04. Lipocine has a one year low of $2.68 and a one year high of $11.79. The firm has a market cap of $19.42 million, a price-to-earnings ratio of -4.78 and a beta of 1.52.

Lipocine (NASDAQ:LPCN) last posted its earnings results on Thursday, May 8th. The specialty pharmaceutical company reported ($0.35) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.35). The firm had revenue of $0.09 million for the quarter, compared to analysts’ expectations of $0.35 million.

Institutional Investors Weigh In On Lipocine

An institutional investor recently raised its position in Lipocine stock. Geode Capital Management LLC lifted its position in shares of Lipocine Inc. (NASDAQ:LPCN) by 6.0% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 57,464 shares of the specialty pharmaceutical company’s stock after acquiring an additional 3,248 shares during the quarter. Geode Capital Management LLC owned 1.07% of Lipocine worth $280,000 as of its most recent SEC filing. Institutional investors own 9.11% of the company’s stock.

Lipocine Company Profile

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.